Previous close | 0.1135 |
Open | 0.1145 |
Bid | 0.1135 x 0 |
Ask | 0.1149 x 0 |
Day's range | 0.1135 - 0.1148 |
52-week range | 0.0300 - 0.1600 |
Volume | |
Avg. volume | 1,133,630 |
Market cap | 114.221M |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ANN ARBOR, Mich., July 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces the launch of its third and largest production cycle of the 2024 spider silk production season. This cycle is being released in a set of scheduled batches, the first of which is already in production. This batch process is designed to address the upcoming peak of the rainy season while driving Kraig Labs toward its 2024 production volume goals. This expan
ANN ARBOR, Mich., July 15, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today the completion of phase one construction for its production facility expansion. This project was completed on budget and on schedule. This facility is now ready to support the Company's third production wave, which will begin this month. This additional production space will allow Kraig Labs to continue its production expansion during the rainy seas
ANN ARBOR, Mich., July 08, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has signed a production agreement for the manufacturing of its recombinant spider silk technology. This production agreement builds upon the Company's success with the rollout of its new spider silk production hybrids earlier this year. Under the terms of this agreement, Kraig Labs will work with silk manufacturers to adapt their existing pr